

Table 3. Downregulated Genes in ALS Motor Neurons (Bottom 30)

GeneBank No.	Gene Name	Fold Change (ALS/control)
NM_004378	Cellular retinoic acid-binding protein 1 (CRABP1)	0.12
NM_004430	Early growth response 3 (EGR3)	0.14
NM_005558	Ladinin 1	0.15
NM_003603	Arg/Abl-interacting protein ArgBP2	0.15
NM_000117	Emerin (Emery-Dreifuss muscular dystrophy)	0.15
NM_004357	CD151 antigen	0.15
X06820	Ras homolog gene family member B (RHOB)	0.15*
NM_003834	Regulator of G-protein signalling 11	0.16
NM_002960	S100 calcium-binding protein A3	0.16
NM_006289	Talin	0.16
NM_000964	Retinoic acid receptor, α	0.17
NM_002391	Midkine	0.17
M96944	Paired box protein PAX-5	0.17*
M74178	Hepatocyte growth factor-like protein	0.17*
NM_003822	Nuclear receptor subfamily 5, group A, member 2	0.17
NM_001188	BCL2-antagonist/killer 1; Bak	0.18
NM_000733	CD3E antigen, epsilon polypeptide (TiT3 complex)	0.18
NM_000408	Glycerol-3-phosphate dehydrogenase 2 (mitochondrial)	0.18
NM_000156	Guanidinoacetate <i>N</i> -methyltransferase	0.18*
M11886	Major histocompatibility complex, class I, C	0.18*
NM_003865	Homeo box (expressed in ES cells) 1	0.18
M36340	ADP-ribosylation factor 1 (ARF1)	0.18*
NM_001725	Bactericidal/permeability-increasing protein	0.18
NM_005334	Host cell factor C1 (VP16-accessory protein)	0.19
NM_004192	Acetylserotonin <i>O</i> -methyltransferase-like	0.19
NM_002684	Postmeiotic segregation increased 2-like 11	0.19
M11233	cathepsin D precursor (CTSD)	0.19*
NM_002313	Actin binding LIM protein 1	0.19
NM_002196	Insulinoma-associated 1	0.19
NM_002277	Keratin, hair, acidic, 1	0.19

Gene expression levels are expressed as means of fold-change, which is calculated by dividing the signals of each ALS sample by those of control samples, in the 5 or 10 (denoted by asterisk) patients with ALS.
ALS = amyotrophic lateral sclerosis.

ron-specific upregulated and downregulated gene expression commonly observed in five patients.

Clusters 1 (SOM1) and 6 (SOM6) contains 110 and 169 genes, respectively, that generally are downregulated in spinal motor neurons in all five cases examined, and those are known to be involved in the functional category of cell surface antigens and cell receptors, transcription, and cytoskeleton, whereas clusters 24 (SOM24) and 25 (SOM25) have 191 and 93 genes, respectively, that are predominantly upregulated in spinal motor neurons in all cases and belong to the functional category of cell signaling with extracellular communication, and cell death-associated proteins. The pattern of subcellular localization of their gene products also confirms the characteristics of the functional categories of upregulated and downregulated genes, that is, that plasma membrane and cytoskeletal proteins are more downregulated, and extracellular secreted proteins are more upregulated, in ALS motor neurons. All the genes listed in Table 3 are included in SOM1 and SOM6, whereas SOM24 and SOM25 do not contain all of the genes listed in Table 2. The former group of genes, with downregulation in motor

neurons, included BCL2-antagonist/killer 1 (Bak) and TrkC receptor. Regarding genes related to transcription, early growth response 3 (EGR3), cellular retinoic acid-binding protein 1 (CRABP1), retinoic acid receptors, and Musashi 1 were included in SOM1 and SOM6 as downregulated genes. The expression of dynactin and microtubule-associated proteins (MAPs), which belong to the functional category of cytoskeleton and axonal transport, was downregulated in ALS motor neurons. On the other hand, KIAA0231 and acetyl-coenzyme A transporter were classified into the upregulated genes in motor neurons of ALS. Regarding genes related to cell death, the expression of cyclins A1 and C, death receptor 5 (DR5), and interleukin-1 receptor antagonist was upregulated together with that of NF- κ B, tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6), and caspase-1, -3, and -9 in SOM24 and SOM25. For genes in the category of trophic factor cell signaling with extracellular communication, CNTF, HGF, and glial cell line-derived neurotrophic factor (GDNF) were upregulated in ALS motor neurons, whereas midkine was downregulated. The expression of vascular endothelial growth factor as

Table 4. Upregulated Genes in Spinal Ventral Horns of ALS (Top 30)

GeneBank	Gene Name	Fold Change (ALS/control)
NM_000508	Fibrinogen, A α polypeptide	8.23
D86984	KIAA0231	6.09
NM_001801	Cysteine dioxygenase, type I	5.81
X02544	α -1-Acid glycoprotein 1 precursor	5.59
NM_001973	ELK4, ETS-domain protein (SRF accessory protein 1)	5.12
NM_000021	Presenilin 1 (Alzheimer disease 3)	5.00
NM_002097	General transcription factor IIIA	4.96
U08015	Transcription factor NF-ATc	4.96
M57730	Ephrin-A1	4.88
U91618	Neurotensin/neuromedin N precursor	4.79
AF000936	SH3-binding protein 2	4.50
NM_002949	Mitochondrial ribosomal protein L12	4.11
NM_002386	Melanocortin 1 receptor	4.03
NM_001991	Enhancer of zeste (Drosophila) homolog 1	3.93
NM_000947	Primase, polypeptide 2A (58kDa)	3.92
NM_000239	Lysozyme (renal amyloidosis)	3.88
NM_001550	Interferon-related developmental regulator 1	3.67
NM_004602	Staufen (Drosophila, RNA-binding protein)	3.66
NM_000063	Complement component 2	3.58
NM_004651	Ubiquitin-specific protease 11	3.54
NM_000397	Cytochrome b-245, β polypeptide	3.51
NM_002056	Glutamine-fructose-6-phosphate transaminase 1	3.41
L25851	Integrin α E precursor (ITGAE)	3.36
NM_004616	Transmembrane 4 superfamily member 3	3.21
NM_003720	Down syndrome critical region gene 2	3.18
J04536	leukosialin precursor; sialophorin	3.15
X06745	DNA polymerase alpha catalytic subunit	3.15
K03020	Phenylalanine-4-hydroxylase (PAH)	3.14
NM_001329	C-terminal binding protein 2	3.14
NM_000276	Oculocerebrorenal syndrome of Lowe	3.13

Gene expression levels are expressed as means of fold-change, which is calculated by dividing the signals of each ALS sample by those of control samples, in the five patients with ALS.
ALS = amyotrophic lateral sclerosis.

well as NT-3 was unchanged. Furthermore, the genes whose expression was altered significantly in spinal ventral horn homogenates as shown in Tables 4 and 5 showed similar alterations to some extent in the remaining motor neurons. However, the upregulated genes, such as integrin α E and sialophorin for cell adhesion, which were demonstrated to be spinal ventral horn-derived (see Table 4) as well as spinal motor neuron-derived (Table 2) genes, were not sorted out into SOM24 and SOM25, indicating that their upregulation occurred predominantly in glial cells.

Data Confirmation with Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction, In Situ Hybridization, and Immunohistochemistry

To assure the validity of the gene expression levels detected by microarray analysis, we performed quantitative real-time RT-PCR analysis on some genes of interest using a TaqMan PCR system. Because LCM-isolated motor neurons did not contain enough RNA to perform real-time RT-PCR analysis, only selected genes were assessed in motor neurons, and for other genes the spinal ventral horn homogenates were used as

the template for quantitative RT-PCR. When the extent of increase or decrease of gene expression levels was expressed as the ratio of the genes of interest to GAPDH, acetyl-CoA transporter and KIAA0231 were significantly increased 3.1-fold ($p < 0.001$) and 3.3-fold ($p < 0.01$) in spinal motor neurons of ALS, respectively (Fig 3). EGR3 expression decreased to 0.27-fold ($p < 0.01$) in ALS motor neurons. These mRNA alterations were also detected at comparable levels when using spinal ventral horn homogenates of ALS (acetyl-CoA transporter, 1.8-fold increase [$p < 0.005$]; KIAA0231, 2.3-fold increase [$p < 0.05$]; and EGR3, 0.41-fold decrease [$p < 0.01$]). In addition, the gene expression of Bak and TrkC was downregulated 0.53-fold ($p < 0.01$) and 0.40-fold ($p < 0.05$) in ALS, respectively. Moreover, increases of ephrin A1 and cyclin C expression were observed to the extents of 2.5-fold ($p < 0.05$) and 4.9-fold ($p < 0.01$), whereas dynactin 1 mRNA was downregulated 0.44-fold ($p < 0.01$), and CRABP1 mRNA was also downregulated to 0.59-fold ($p < 0.01$) in ALS.

To further verify the localization and extent of expression of genes of interest, we performed in situ hy-

Table 5. Downregulated Genes in Spinal Ventral Horns of ALS (Bottom 30)

GeneBank	Gene Name	Fold Change (ALS/control)
NM_000843	Glutamate receptor, metabotropic 6	0.22
NM_000730	cholecystokinin A receptor	0.24
NM_003134	Signal recognition particle 14kDa	0.26
NM_003163	Syntaxin 1B	0.27
NM_006476	ATP synthase, H ⁺ transporting, mitochondrial F1F0, subunit g	0.27
NM_001610	Acid phosphatase 2, lysosomal	0.28
NM_003108	SRY (sex determining region Y)-box 11	0.29
NM_001446	Fatty acid binding protein 7, brain	0.30
NM_004583	RAB5C, member RAS oncogene family	0.31
NM_001125	ADP-ribosylarginine hydrolase	0.31
NM_003320	Tubby (mouse) homolog	0.31
NM_001731	B-cell translocation gene 1, antiproliferative	0.31
NM_000999	Ribosomal protein L38	0.32
NM_004128	General transcription factor IIF, polypeptide 2 (30kDa subunit)	0.32
NM_001765	CD1C antigen, c polypeptide	0.32
NM_004430	Early growth response 3 (EGR3)	0.33
K00558	Tubulin, α , ubiquitous	0.33
NM_006732	FBJ murine osteosarcoma viral oncogene homolog B	0.33
NM_002040	GA-binding protein transcription factor, α subunit (60kDa)	0.34
NM_006161	Neurogenin 1	0.35
NM_002684	Postmeiotic segregation increased 2-like 11	0.35
NM_000801	FK506-binding protein 1A (12kDa)	0.35
NM_001051	Somatostatin receptor 3	0.35
NM_005017	Phosphate cytidylyltransferase 1, choline, alpha isoform	0.36
NM_004927	Chromosome 11 open reading frame 4	0.36
NM_000046	Arylsulfatase B	0.37
NM_004378	Cellular retinoic acid-binding protein 1 (CRABP1)	0.37
NM_001998	Fibulin 2	0.38
NM_001839	Calponin 3, acidic	0.38
NM_001183	ATPase, H ⁺ transporting, lysosomal, subunit 1	0.39

Gene expression levels are expressed as means of fold-change, which is calculated by dividing the signals of each ALS sample by those of control samples, in the five patients with ALS.
ALS = amyotrophic lateral sclerosis.

bridization on selected genes. The mRNAs for acetyl-CoA transporter, KIAA0231, and EGR3 were localized in the remaining motor neurons (Fig 4). Spinal motor neurons overexpressed acetyl-CoA transporter and KIAA0231 in ALS, whereas EGR3 was underexpressed. Moreover, TrkC, CRABP1, Bak, and dynactin 1 gene expression was found in motor neurons, and those signals were reduced in ALS. DR5 signals were increased in motor neurons in ALS. Cyclin C signals with punctate immunoreactivity were increased in the cytoplasm as well as in nuclei in ALS motor neurons. The nuclear staining of motor neurons for cyclin C was more prominent in ALS compared with controls.

Discussion

Although reports about differential gene expression using the postmortem spinal cords, including those of patients with ALS, have been published,^{26,27} the precise gene expression profiles of the degenerating motor neurons themselves have remained to be elucidated. Laser-captured dissection of motor neurons and subsequent microarray analysis are the most appropriate approaches to understanding the motor neuron-specific

gene expression profile related to the motor neuron degeneration process in sporadic ALS, because these approaches eliminate bias of motor neuron loss, reactive astroglial proliferation, and other cellular reactions. Indeed, serine kinase has been reported to be underexpressed in ALS spinal cord gray matter,²⁷ but this study showed it was overexpressed in isolated motor neurons, suggesting that the reported underexpression in whole gray matter was influenced by the decreased motor neuron population. In contrast, cathepsin D expression was downregulated in the ALS motor neurons in this study, whereas it was increased in spinal cord gray matter in a previous report,²⁷ indicating its up-regulation in glial cells. In addition, clustering analyses showed that the gene expression profile in the spinal motor neurons was substantially different from that in the whole homogenates of spinal ventral horn gray matter.

The overall microarray analysis using spinal ventral horn homogenates showed gene expression changes in less than 1% of genes examined with more genes showing increased than decreased expression. On the other hand, the motor neuron-specific microarray analysis




Fig 2. Clustering of gene expression in spinal motor neurons and spinal ventral horns. (A) Hierarchical clustering of gene expression in spinal motor neurons and ventral horns. The dendrogram was produced by hierarchical clustering of relative expression levels of 4,845 genes (rows) in five spinal homogenate and five motor neuron samples (columns) in making a total of 48,450 data points. Visual representation is shown with green representing downregulated (<0.44), black representing intermediate, and red representing upregulated (>2.28). The hierarchical clustering successfully detects two large clusters of amyotrophic lateral sclerosis (ALS), discriminating between spinal homogenates of ventral horns (samples V1 [ALS1], V2 [ALS10], V3 [ALS3], V4 [ALS14], and V5 [ALS13]) and motor neurons (samples M6 [ALS1], M7 [ALS10], M8 [ALS14], M9 [ALS11], and M10 [ALS7]), with a correlation coefficient of 0.446 at the branching point. (B) Principal component analysis of spinal motor neurons and ventral horns. Principal component analysis by six components for the 4,845 genes shows two main clusters consisting of spinal motor neurons (M6–10) and homogenates (V1–5). The number of patients corresponds to those in the dendrogram. (C) Self-organizing map (SOM) analysis of spinal motor neurons and ventral horns. The 4,845 genes are grouped into 25 clusters, the optimal size of which is calculated from gap statistics analysis. In SOM1 and SOM6, most genes are downregulated and in SOM24 and SOM25 the majority of genes are upregulated commonly in isolated motor neurons of five cases (M6–10). The numbers of genes are given at the top, and selected genes are listed for clusters 1, 6, 24, and 25 in Table 6.

showed that the proportion of significantly downregulated genes was 3% of the examined genes, whereas that of upregulated genes was one third of the downregulated genes. Moreover, the genes found to be downregulated specifically in motor neurons were not found to be downregulated in ventral horns, except for three genes with high expression levels. These results strongly support the notion that microarray analysis of laser-captured isolated spinal motor neurons has an advantage especially for the detection of motor neuron-specific downregulated transcripts.

In the differentially expressed genes, cell death-associated genes and genes related to cell signaling were characteristically upregulated in ALS motor neurons, whereas the genes categorized into cytoskeleton and

transcription were downregulated. In the prominently altered genes of interest related to the cell death pathway, acetyl-coenzyme A transporter, which has been cloned and shown to encode a protein with multitransmembranous spanning domains,²⁸ was overexpressed in ALS motor neurons. Acetyl-CoA transporter functions as a cofactor for acetylation of gangliosides as well as vesicular transport of acetylcholine, which is synthesized from acetyl-CoA and choline. Acetylation has been documented to suppress proapoptotic activity of GD3 ganglioside, which increased in ALS neural tissues, as previously shown.^{29,30} These results suggest that enhanced expression of acetyl-CoA transporter may be related to the antiapoptotic mechanism for cholinergic motor neuron degeneration in ALS.

Table 6. Selected Genes Characterized by SOM (select each 15)

GeneBank	Gene Name	Fold Change (ALS/control)
SOM1/6: genes downregulated in ALS motor neurons		
NM_002695	Polymerase (RNA) II (DNA directed) polypeptide E (25kD)	0.20
M24857	Retinoic acid receptor gamma 1 (RAR-γ 1)	0.20
NM_002375	Microtubule-associated protein 4	0.20
NM_001651	Aquaporin 5	0.21
NM_003178	Synapsin II	0.22
NM_004624	Vasoactive intestinal peptide receptor 1	0.23
NM_001740	Calbindin 2, (29kD, calretinin)	0.24
M73812	G1/S-specific cyclin E (CCNE)	0.25
NM_003206	Transcription factor 21	0.25
NM_004082	Dynactin 1 (p150)	0.30
U05012	TRK-C; NT-3 growth factor receptor precursor	0.31
NM_003632	Contactin associated protein 1	0.32
NM_005910	Microtubule-associated protein tau	0.49
NM_002373	Microtubule-associated protein 1A	0.51
NM_002442	Musashi (Drosophila) homolog 1	0.52
SOM24/25: genes upregulated in ALS motor neurons		
M60718	Hepatocyte growth factor (HGF)	3.42
L20814	Glutamate receptor subunit 2 (GLUR-2)	3.34
K02268	β-neoendorphin-dynorphin precursor	3.13
L19063	Glial cell line-derived neurotrophic factor (GDNF)	3.08
NM_005543	Insulin-like 3	2.79
J04088	DNA topoisomerase II alpha (TOP2A)	2.58
M22489	Bone morphogenetic protein 2A (BMP2A)	2.57
U51004	Hint protein; protein kinase C inhibitor	2.26
M87507	Caspase 1, interleukin-1 β convertase precursor	2.21
NM_006196	Poly(rC)-binding protein 1	2.16
L29511	Growth factor receptor-bound protein 2	2.04
U78798	TRAF6	1.98
NM_001229	Caspase 9, apoptosis-related cysteine protease	1.89
U84388	Caspase and rip adaptor with death domain (CRADD)	1.83
U13737	Caspase-3	1.77

Gene expression levels are expressed as means of fold-change, which is calculated by dividing the signals of each ALS sample by those of control samples, in the five patients with ALS. Genes listed in Tables 2 and 3 are excluded. SOM = self-organizing map.

KIAA0231 was one of the mostly overexpressed genes in ALS motor neurons, but the function of this gene product is not known.

In the greatly downregulated genes of interest related to transcription, EGR3, whose expression was remarkably reduced in motor neurons of ALS, is a zinc-finger immediate-early transcription factor that is important for neurotrophin-3 (NT-3) regulation. It is known that EGR3 knockout mice develop gait ataxia, scoliosis, resting tremors, and ptosis due to the degeneration of muscle spindles, through disruption of NT-3 regulation.³¹ In ALS motor neurons, TrkC receptor for NT-3 was underexpressed, whereas NT-3 expression was not changed. The finding about TrkC-null mutant and NT-3-null mutant mice show that NT-3-TrkC signaling is required to maintain Ia afferent central synapses of DRG neurons.³² The marked downregulation of EGR3 in spinal motor neurons may disrupt sensory-motor connections by decreasing NT-3-TrkC signaling, resulting in motor neuron degeneration.

For neurotrophic support for ALS motor neurons, this study showed the overexpression of CNTF, GDNF, and HGF involved in the functional category of cell signaling, suggesting that these neurotrophic factors would be secondarily and compensatorily upregulated after motor neuron degeneration. Indeed, GDNF expression has been reported to increase in the spinal cords and decrease in the muscles of sporadic ALS patients.³³ In contrast with these neurotrophic factors, midkine was one of the significantly downregulated neurotrophic factors. Because midkine plays important roles in promotion of neuronal survival as well as modulation of neuromuscular junctions,³⁴ its underexpression may be related to motor neuron degeneration. In addition, the gene expression of vascular endothelial growth factor, which has been identified as a critical factor for motor neuron degeneration,³⁵⁻³⁷ did not change significantly in gene expression in this study. SOD1 gene expression was not altered in spinal motor neurons and ventral horns. Moreover, the gene expres-




Fig 3. Quantitative real-time reverse transcription polymerase chain reaction verification of the selected genes. Expression levels of acetyl-coenzyme A transporter, EGR3, KIAA0231, CRABP1, Bak, TrkC, ephrin A1, cyclin C, dynactin 1, and GAPDH were measured using spinal motor neurons (M) and ventral horns (V), and those of the target genes were normalized against the GAPDH level. The relative expression levels are expressed as mean \pm standard error for 13 amyotrophic lateral sclerosis (ALS) cases and 11 controls. Gene names (Genebank accession number), primers and probe sequences (forward primer, reverse primer, and TaqMan probe; 5' to 3' sequence) were as follows: [acetyl-CoA transporter: D88152] (GGGTTACTTTTTGGGCAATG, AACGATTCTCTGGGTTGAG, FAM-TTGGCCCTTGAATCTGCCGA-TAMRA); [Bak: NM_001188] (CTGGAAGATCAGCACCTAAG, CCCCTCTCCTAGTAGGTCCTG, FAM-TGCTCCCATTCTCCCTCCG-TAMRA); [CRABP1: NM_004378] (TGCAGGAGTTTAGCCACTTG, CTCACGGTCCAGTAGGTTT, FAM-TGAGAACAAGATCCATGCACCCA-TAMRA); [cyclin C: M74091] (TGAGCAGTGGAGAATTTTCG, ACCCTCTCCTTCACTGT, FAM-TGCCAAAACCAAAACCACCTCCA-TAMRA); [dynactin 1: NM_004082] (ATGTGAATCGGGAAGTACA, GGGCCTTAGTCTCAGCAAAC, FAM-TGAGAGGCAACAGCAGCCAC-TAMRA); [EGR3: NM_004430] (CTTCCCCATGATTCCTGACT, TTGAATGCCTTGATG-TCTC, FAM-TTCCAGGGCATGGACCCAT-TAMRA); [ephrin A1: M57730] (GGCAAGGAGTTCAAAGAAGG, TCACCTTCAACCTCAAGCAG, FAM-CCATCCACCAGCATGAAGACCG-TAMRA); [GAPDH: NM_002046] (TCAAGAAGGTGGTGAAGCAG, GGTGTCGCTGTTGAAGTCAG, FAM-CCTCAAGGGCATCCTGGGCT-TAMRA); [KIAA0231: D86984] (CAACGGTCTTCCAGACAATG, GAGGTTGACCAGCTGTGAGA, FAM-TCCCAGAGGTGAAGCTGCCCTC-TAMRA); and [TrkC: U05012] (TGAGAACCCCCAGTACTTCC, TCAGCAGGATGTCTCTCCTC, FAM-CTGCCACAAGCCGGACACGT-TAMRA).

sion level of GluR2 was upregulated, as shown by its classification in SOM25, but the expression of its editing enzyme (adenosine deaminase, RNA-specific, 2; ADAR2) was not altered in this study, although the editing efficiency of GluR2 mRNA has been demonstrated to be low in spinal motor neurons of ALS.³⁸

Genes subject to transcriptional regulation constitute a crucial part of the whole human genome as demonstrated by human genome projects.³⁹ In addition to the gene expression of EGR3, the gene expression of

retinoic acid receptor α and γ together with cellular retinoic acid-binding protein 1 (CRABP1), and Musashi 1, all of which are known to be inducers of neuronal differentiation,^{40,41} was downregulated in spinal motor neurons of ALS. The dysregulation of retinoid receptor and retinol binding protein has been reported in the postmortem spinal cords of ALS and SOD1 mutant mice.^{17,26} These interesting results imply the potential involvement of the differentiation signals in maintaining motor neuron integrity, which




Fig 4. *In situ* hybridization and immunohistochemistry of the selected genes. Representative *in situ* hybridization is shown for acetyl-COENZYME A transporter, EGR3, KIAA0231, CRABP1, Bak, TrkC, DR5, and dynactin 1. The antisense probe (AS) detects positive signals for the expression of each gene in spinal motor neurons for ALS and/or controls, but the sense probe (S) does not. Lipofuscin granules are seen as yellowish granules. Immunohistochemistry was performed for cyclin C, and nuclear staining was prominent in ALS motor neurons. Arrows denote the nuclei. Bars = 25 μ m.

might be impaired in the neurodegenerative process of ALS. Among the genes related to transcriptional regulation, the number of significantly downregulated genes was twofold greater than that of the upregulated ones in ALS motor neurons. These downregulated transcription-related genes were not restricted to genes regulating neuronal differentiation as neuron-specific cellular properties, but also included genes such as RNA polymerase and transcription factors, which regulate general cellular functions. These observations suggest that downregulation of transcriptional activity may be the reflection of motor neuron dysfunction because of a wide range of impairments of cellular maintenance systems.

Interestingly, the expression of dynactin 1, which recently has been identified as a causative gene for human motor neuron disease,⁴² was reduced in ALS motor neurons. Some other motor proteins including the kinesin family responsible for anterograde axonal trans-

port and dyneins for retrograde axonal transport were not changed significantly, but the expression levels of MAPs 1A, 4, and tau were decreased, shown by their classification in SOM1 and SOM6. The impairment of axonal transport is thought to be an early event of motor neuron degeneration, and especially the protein levels of MAPs 1A and tau have been reported to decrease early before the onset of symptoms in mutant SOD1 transgenic mice.⁴³⁻⁴⁵ The upregulation of ubiquitin-specific protease 11 (USP11), listed in Tables 2 and 3, also may be related to microtubule abnormality because the RanGTP-associated protein RanBPM, which is required for correct nucleation of microtubules, is the enzymatic substrate for USP11.⁴⁶ The present results imply that retrograde axonal transport, especially that associated with dynactin, might be affected even at the terminal stage of ALS and be crucial for motor neurons, although cytoskeletal proteins are the major functional group in the downregulated genes.

As for the death signals and inflammatory factors, we previously have reported that these genes were significantly upregulated in the spinal cord of mutant SOD1 transgenic mice,^{15,17} suggesting that these inflammatory and apoptotic death signals play a crucial role in concert with motor neuron degeneration and inflammatory cellular reactions, including microglial activation.^{7,47} However, in sporadic ALS spinal cords, the expression profiles of inflammation- and death signal-related genes are somewhat different from those in the Tg mouse model. Death receptor 5 (TNF receptor 10b, TNFR10b), TNF receptor-associated factor 6 (TRAF 6), interleukin-1 receptor antagonist, and ephrin A1 were overexpressed in ALS motor neurons, whereas the expression levels of the respective ligands or inducers, TNF- α , TNF superfamily member 10 (TRAIL) and IL-1 β , were not markedly changed in either motor neurons or ventral horn homogenates. Because TNF- α was prominently upregulated in the Tg mouse spinal cords,¹⁷ its almost unchanged expression level in sporadic ALS was a surprising observation. Many other inflammation-related genes were also not significantly upregulated in human ALS spinal cords, in contrast with the findings in animal models. Far less invasion and activation of microglia, a major source of TNF- α , IL-1 β , and many other inflammatory factors, were seen in human ALS spinal cords at the terminal autopsy stage as compared with those of Tg mice,⁴⁸ which could explain these differences.

Genes related to apoptotic pathways, caspase-1, -3, -9, caspase, and RIP adaptor with death domain (CRADD), were upregulated in ALS motor neurons in SOM analysis (SOM24 and SOM25), and an anti-apoptotic factor, NF- κ B, was markedly upregulated. Although Bax, a proapoptotic Bcl-2 family member, has been reported to increase in ALS motor neurons,^{49,50} and another member, Bak, was underexpressed in this study, the expression of Bcl-2 and Bcl-xL, antiapoptotic Bcl-2 family members was not significantly altered in motor neurons, possibly suggesting that Bcl-2 family members are not primarily involved in motor neuron degeneration in sporadic ALS. Cyclin A1 and C were upregulated (SOM25) and cyclin E was downregulated (SOM1) in ALS motor neurons. These cell cycle regulators are specific to G1/S phase transition, and upregulation of these cyclins enhances arrest in G1/S phase, preventing entry into S phase. Our finding on cyclin expression support the recently reported view that G1/S phase is aberrantly activated in ALS motor neurons, eventually inducing motor neuron death.⁵¹ The subcellular localization of cyclin C in the nucleus may trigger cell death signaling mechanisms. These factors related to the cell death signaling pathway, TNFR, TRAF6, CRADD, caspases, cyclins, Bak, and NF- κ B may be involved in the motor neuron degeneration process in sporadic ALS, although

we cannot simply state that an apoptotic process is present in ALS motor neurons, as has been suggested by many histological analyses.⁶ Because neuronal cell degeneration and the eventual neuronal cell death process are the results of interactions of complex pathways involving many factors and signaling molecules, we need to further elucidate the pathophysiological significance of these factors with altered expression levels in ALS motor neurons.

Microarray analysis on the laser-captured motor neurons provided us with significant information about motor neuron degeneration and dysfunction in sporadic ALS patients. Such information cannot be obtained by whole spinal cord tissue microarray assay,⁵² as discussed above. Although this study was performed on postmortem patients' tissues, the remaining individual motor neurons would express ongoing or even early molecular events in the neurodegeneration process, because motor neurons in the remaining motor neuron population randomly enter into the degeneration process among up to the terminal stage in ALS.⁵³ We need to study larger numbers of ALS patients, and to understand the pathophysiological roles of candidate genes identified by the combined methodology of DNA microarray analysis and LCM, compared with other neurodegeneration processes. This methodology provides crucial clues about candidate genes whose related products might hamper the disease process of ALS.

This work was supported by a Center of Excellence grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and grants from the Ministry of Health, Labor and Welfare of Japan.

References

1. Ince PG, Lowe J, Shaw PJ. Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology. *Neuropathol Appl Neurobiol* 1998;24:104-117.
2. Bunina TL. On intracellular inclusions in familial amyotrophic lateral sclerosis. *Korsakov J Neuropath Psychiat* 1962;62:1293-1296.
3. Okamoto K, Hirai S, Amari M, et al. Bunina bodies in amyotrophic lateral sclerosis immunostained with rabbit anti-cystatin C serum. *Neurosci Lett* 1993;162:125-128.
4. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. *Nat Rev Neurosci* 2001;2:806-819.
5. Bergeron C. Oxidative stress: its role in the pathogenesis of amyotrophic lateral sclerosis. *J Neurol Sci* 1995;129(suppl):81-84.
6. Sathasivam S, Ince PG, Shaw PJ. Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. *Neuropathol Appl Neurobiol* 2001;27:257-274.
7. Hand CK, Rouleau GA. Familial amyotrophic lateral sclerosis. *Muscle Nerve* 2002;25:135-159.
8. Ishigaki S, Liang Y, Yamamoto M, et al. X-Linked inhibitor of apoptosis protein is involved in mutant SOD1-mediated neuronal degeneration. *J Neurochem* 2002;82:576-584.

9. Kawahara Y, Ito K, Sun H, et al. Glutamate receptors: RNA editing and death of motor neurons. *Nature* 2004;427:801.
10. Niwa J, Ishigaki S, Hishikawa N, et al. Dorsin ubiquitylates mutant SOD1 and prevents mutant SOD1-mediated neurotoxicity. *J Biol Chem* 2002;277:36793–36798.
11. Hishikawa N, Niwa J, Doyu M, et al. Dorsin localizes to the ubiquitylated inclusions in Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and amyotrophic lateral sclerosis. *Am J Pathol* 2003;163:609–619.
12. Luo J, Isaacs WB, Trent JM, Duggan DJ. Looking beyond morphology: cancer gene expression profiling using DNA microarrays. *Cancer Invest* 2003;21:937–949.
13. Alizadeh AA, Ross DT, Perou CM, van de Rijn M. Towards a novel classification of human malignancies based on gene expression patterns. *J Pathol* 2001;195:41–52.
14. Luo L, Salunga RC, Guo H, et al. Gene expression profiles of laser-captured adjacent neuronal subtypes. *Nat Med* 1999;5:117–122.
15. Ando Y, Liang Y, Ishigaki S, et al. Caspase-1 and -3 mRNAs are differentially upregulated in motor neurons and glial cells in mutant SOD1 transgenic mouse spinal cord: a study using laser microdissection and real-time RT-PCR. *Neurochem Res* 2003;28:839–846.
16. Ginsberg SD, Hemby SE, Lee VM, et al. Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. *Ann Neurol* 2000;48:77–87.
17. Yoshihara T, Ishigaki S, Yamamoto M, et al. Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. *J Neurochem* 2002;80:158–167.
18. Kamme F, Salunga R, Yu J, et al. Single-cell microarray analysis in hippocampus CA1: demonstration and validation of cellular heterogeneity. *J Neurosci* 2003;23:3607–3615.
19. Terao S, Sobue G, Hashizume Y, et al. Disease-specific patterns of neuronal loss in the spinal ventral horn in amyotrophic lateral sclerosis, multiple system atrophy and X-linked recessive bulbospinal neuronopathy, with special reference to the loss of small neurons in the intermediate zone. *J Neurol* 1994;241:196–203.
20. Sobue G, Hashizume Y, Yasuda T, et al. Phosphorylated high molecular weight neurofilament protein in lower motor neurons in amyotrophic lateral sclerosis and other neurodegenerative diseases involving ventral horn cells. *Acta Neuropathol (Berl)* 1990;79:402–408.
21. Bohm M, Wieland I, Schutze K, Rubben H. Microbeam MOMEt: non-contact laser microdissection of membrane-mounted native tissue. *Am J Pathol* 1997;151:63–67.
22. Watanabe H, Tanaka F, Doyu M, et al. Differential somatic CAG repeat instability in variable brain cell lineage in dentatorubral pallidoluysian atrophy (DRPLA): a laser-captured microdissection (LCM)-based analysis. *Hum Genet* 2000;107:452–457.
23. Schutze K, Lahr G. Identification of expressed genes by laser-mediated manipulation of single cells. *Nat Biotechnol* 1998;16:737–742.
24. Wang J, Delabie J, Aasheim H, et al. Clustering of the SOM easily reveals distinct gene expression patterns: results of a re-analysis of lymphoma study. *BMC Bioinformatics* 2002;3:36–44.
25. Ross ME, Zhou X, Song G, et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. *Blood* 2003;102:2951–2959.
26. Malaspina A, Kaushik N, de Belleruche J. Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays. *J Neurochem* 2001;77:132–145.
27. Dangond F, Hwang D, Camelo S, et al. The molecular signature of late-stage human ALS revealed by expression profiling of post-mortem spinal cord gray matter. *Physiol Genomics* 2004;16:229–239.
28. Kanamori A, Nakayama J, Fukuda MN, et al. Expression cloning and characterization of a cDNA encoding a novel membrane protein required for the formation of O-acetylated ganglioside: a putative acetyl-CoA transporter. *Proc Natl Acad Sci USA* 1997;94:2897–2902.
29. Malisan F, Franchi L, Tomassini B, et al. Acetylation suppresses the proapoptotic activity of GD3 ganglioside. *J Exp Med* 2002;196:1535–1541.
30. Rapport MM, Donnenfeld H, Brunner W, et al. Ganglioside patterns in amyotrophic lateral sclerosis brain regions. *Ann Neurol* 1985;18:60–67.
31. Chen HH, Tourtellotte WG, Frank E. Muscle spindle-derived neurotrophin 3 regulates synaptic connectivity between muscle sensory and motor neurons. *J Neurosci* 2002;22:3512–3519.
32. Mears SC, Frank E. Formation of specific monosynaptic connections between muscle spindle afferents and motoneurons in the mouse. *J Neurosci* 1997;17:3138–3135.
33. Yamamoto M, Sobue G, Yamamoto K, et al. Expression of glial cell line-derived neurotrophic factor mRNA in the spinal cord and muscle in amyotrophic lateral sclerosis. *Neurosci Lett* 1996;204:117–120.
34. Zhou H, Muramatsu T, Halfter W, et al. A role of midkine in the development of the neuromuscular junction. *Mol Cell Neurosci* 1997;10:56–70.
35. Oosthuysen B, Moons L, Storkebaum E, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. *Nat Genet* 2001;28:131–138.
36. Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. *Nat Genet* 2003;34:383–394.
37. Gros-Louis F, Laurent S, Lopes AA, et al. Absence of mutations in the hypoxia response element of VEGF in ALS. *Muscle Nerve* 2003;28:774–775.
38. Kawahara Y, Ito K, Sun H, et al. Low editing efficiency of GluR2 mRNA is associated with a low relative abundance of ADAR2 mRNA in white matter of normal human brain. *Eur J Neurosci* 2003;18:23–33.
39. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. *Science* 2001;291:1304–1351.
40. Colbert MC, Rubin WW, Linney E, LaMantia AS. Retinoid signaling and the generation of cellular diversity in the embryonic mouse spinal cord. *Dev Dyn* 1995;204:1–12.
41. Sakakibara S, Okano H. Expression of neural RNA-binding proteins in the postnatal CNS: implications of their roles in neuronal and glial cell development. *J Neurosci* 1997;17:8300–8312.
42. Puls I, Jonnakuty C, LaMonte BH, et al. Mutant dynactin in motor neuron disease. *Nat Genet* 2003;33:455–456.
43. Williamson TL, Cleveland DW. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. *Nat Neurosci* 1999;2:50–56.
44. Zhang B, Tu P, Abtahian F, et al. Neurofilaments and orthograde transport are reduced in ventral root axons of transgenic mice that express human SOD1 with a G93A mutation. *J Cell Biol* 1997;139:1307–1315.
45. Farah CA, Nguyen MD, Julien JP, Leclerc N. Altered levels and distribution of microtubule-associated protein before disease onset in a mouse model of amyotrophic lateral sclerosis. *J Neurochem* 2003;84:77–86.

46. Ideguchi H, Ueda A, Tanaka M, et al. Structural and functional characterization of the USP11 deubiquitinating enzyme, which interacts with the RanGTP-associated protein RanBPM. *Biochem J* 2002;367:87-95.
47. Hensley K, Floyd RA, Gordon B, et al. Temporal patterns of cytokines and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. *J Neurochem* 2002;82:365-374.
48. Hall ED, Oostveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. *Glia* 1998;23:249-256.
49. Mu X, He J, Anderson DW, et al. Altered expression of bcl-2 and bax mRNA in amyotrophic lateral sclerosis spinal cord motor neurons. *Ann Neurol* 1996;40:379-386.
50. Ekegren T, Grundstrom E, Lindholm D, Aquilonius SM. Up-regulation of Bax protein and increased DNA degradation in ALS spinal cord motor neurons. *Acta Neurol Scand* 1999;100:317-321.
51. Ranganathan S, Bowser R. Alterations in G(1) to S phase cell-cycle regulators during amyotrophic lateral sclerosis. *Am J Pathol* 2003;162:823-835.
52. Malaspina A, de Belleruche J. Spinal cord molecular profiling provides a better understanding of amyotrophic lateral sclerosis pathogenesis. *Brain Res Brain Res Rev* 2004;45:213-229.
53. Sobue G, Sahashi K, Takahashi A, et al. Degenerating compartment and functioning compartment of motor neurons in ALS: possible process of motor neuron loss. *Neurology* 1983;33:654-657.



Retinoic-acid-concentration-dependent acquisition of neural cell identity during in vitro differentiation of mouse embryonic stem cells

Yohei Okada^{a,b,c}, Takuya Shimazaki^{a,c}, Gen Sobue^b, Hideyuki Okano^{a,c,*}

^aDepartment of Physiology, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan

^bDepartment of Neurology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya 466-8550, Japan

^cCore Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Kawaguchi, Saitama 332-0012, Japan

Received for publication 11 February 2004, revised 19 July 2004, accepted 21 July 2004

Available online 8 September 2004

Abstract

Retinoic acid (RA) is one of the most important morphogens, and its embryonic distribution correlates with neural differentiation and positional specification in the developing central nervous system. To investigate the concentration-dependent effects of RA on neural differentiation of mouse embryonic stem cells (ES cells), we investigated the precise expression profiles of neural and regional specific genes by ES cells aggregated into embryoid bodies (EBs) exposed to various concentrations of RA or the BMP antagonist Noggin. RA promoted both neural differentiation and caudalization in a concentration-dependent manner, and the concentration of RA was found to regulate dorso-ventral identity, i.e., higher concentrations of RA induced a dorsal phenotype, and lower concentrations of RA induced a more ventral phenotype. The induction of the more ventral phenotype was due to the higher expression level of the N-terminus of sonic hedgehog protein (Shh-N) when treated with low concentration RA, as it was abrogated by an inhibitor of Shh signaling, cyclopamine. These findings suggest that the concentration of RA strictly and simultaneously regulates the neuralization and positional specification during differentiation of mouse ES cells and that it may be possible to use it to establish a strategy for controlling the identity of ES-cell-derived neural cells.

© 2004 Elsevier Inc. All rights reserved.

Keywords: Embryonic stem cells; Neural differentiation; Retinoic acid; Sonic hedgehog; N-terminus of Sonic hedgehog; Positional identity; Motor neuron; Morphogen

Introduction

Embryonic stem cells (ES cells) are clonal cell lines derived from the inner cell mass (ICM) of developing blastocysts and under appropriate conditions are capable of proliferating extensively and generating various cell types derived from the three primary germ layers of the embryo in vitro. This pluripotency of ES cells provides a powerful in vitro model for investigating the mechanisms that control differentiation in early embryonic development. The basic strategy for in vitro differentiation usually adopted is to induce cell aggregation into so-called embryoid bodies

(EBs) through suspension culture in nonadhesive dishes or hanging drops. Different inducing conditions during EB formation can drastically affect the proportions of the various cell types that differentiate in EBs. For example, exposure to high-concentration RA strongly drives neural induction, whereas low-concentration RA induces cardiomyocyte differentiation (Rohwedel et al., 1999). Because neural cells represent only a small percentage of cells in EBs cultured in the presence of fetal bovine serum (FBS) and the absence of an exogenous inducer, efficient generation of neural cells requires an additional inductive stimulus or other differentiation method.

There are two major strategies for generating neural cells from mouse ES cells: EB formation and serum-free direct induction. The former includes treatment with high-concentration RA (Bain et al., 1995; Fraichard et al., 1995; Strubing et al., 1995), which has been shown to promote

* Corresponding author. Department of Physiology, Keio University, School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Fax: +81 3 3357 5445.

E-mail address: hidokano@sc.itc.keio.ac.jp (H. Okano).

neural gene expression and repress mesodermal gene expression (Bain et al., 1996), and serum-free culture after EB formation, which enables selection of neural cells (Okabe et al., 1996). Direct induction methods consist of a co-culture system with stromal cell line PA6 as a neural inducer that has been found to have stromal-cell-derived inducing activity (SDIA) (Kawasaki et al., 2000), a low-cell-density neural stem cell (NSC) culture (neurosphere culture) with growth factors (Tropepe et al., 2001), and an adherent monolayer culture method (Ying et al., 2003).

Sequences of events leading to lineage commitment similar to those in vivo are often observed with all of these culture strategies, and, for example, exposure to Noggin or other manipulations that inhibit bone morphogenetic protein (BMPs) signaling, which blocks neural differentiation in the early development, facilitates neural differentiation of ES cells also in vitro (Finley et al., 1999; Gratsch and O'Shea, 2002; Kawasaki et al., 2000; Tropepe et al., 2001).

During the development of the mammalian central nervous system (CNS), the differentiation properties of neural stem cells (NSCs) vary depending on the stage at which they are generated (temporal identity) and their location (positional identity). These properties define the induction and sequential rounds of neurogenesis and gliogenesis, which seem to be regulated by both intrinsic and extrinsic factors, and limit their plasticity (Temple, 2001). Depending on their location, their differentiation is usually regulated by secreting signals that modulate the rostro-caudal or dorso-ventral axis of the body and by regional cues that define the borders of each CNS segment (Hitoshi et al., 2002; Temple, 2001). In view of these characteristics of NSCs, the temporal and positional identity of NSCs derived from ES cells may be controlled in vitro by the conditions under which they differentiate, the same as specification in vivo. Indeed, much interest has been focused on the generation of specific types of neurons or neural progenitors from ES cells by producing these identities with inductive signals, such as fibroblast growth factor (FGF) 8 and Shh, or with SDIA for dopaminergic neurons (Kawasaki et al., 2000, 2002; Kim et al., 2002; Lee et al., 2000; Ying et al., 2003), RA and Shh for motor neurons (Renoncourt et al., 1998; Wichterle et al., 2002), and a combination of SDIA and BMPs for dorsal and neural-crest-derived cells (Mizuseki et al., 2003).

RA is well known as the biologically active form of vitamin A and has been shown to play an important role during embryogenesis (Ross et al., 2000). RA influences neural development in the early stage of CNS development and is required to establish patterned territories of cell groups, which, for example, has been observed in rostro-caudal axis formation, according to the distribution of RA in experiments on *Xenopus* (Blumberg et al., 1997; Sive et al., 1990) and mice (Kessel, 1992; Kessel and Gruss, 1991; Marshall et al., 1992). For these reasons, RA has been thought to be one of the most important extrinsic inductive signals that can be used for neural differentiation of mouse

ES cells in vitro. However, its overall effects have yet to be clearly identified, and precise analysis of alterations of gene expression caused by RA treatment should be useful for establishing proper culture protocols for the differentiation of ES cells. In the present study, we demonstrated that RA promotes neural differentiation and caudalization in a concentration-dependent manner, and that the concentration of RA affects dorso-ventral positional identity, by determining the precise gene expression profiles during differentiation of ES cells.

Materials and methods

ES cell culture

Mouse ES cells (EB3) were maintained and used for induction. ES cells were grown on gelatin-coated (0.1%) tissue culture dishes in standard ES-cell culture medium containing GMEM (Sigma G6148) supplemented with 10% FBS, glutamine (2 mM), nonessential amino acids (0.1 mM), sodium pyruvate (1 mM), 2-mercaptoethanol (2-ME) (0.1 mM), sodium bicarbonate (3 mM), HEPES (5 mM), and mLIF. EB3 is a subline derived from E14tg2a ES cells (Hooper et al., 1987) that was generated by targeted integration of Oct3/4-IRES-BSD-pA vector (Niwa et al., 2000) into the Oct3/4 allele, and it was maintained in the medium containing 10 µg/ml blasticidin S to eliminate differentiated ES cells.

Differentiation of ES cells

For embryoid body (EB) formation, ES cells were detached and dissociated into single cells with 0.25% trypsin-EDTA and then plated onto a bacteriological dish (Kord-Valmark™) in 10 ml of αMEM (Gibco 11900-024) supplemented with 10% FBS, sodium bicarbonate (3 mM), and 0.1 mM 2-ME (EB medium) at a density of 5×10^4 cells/ml. On day 2, various concentrations of all-trans-retinoic acid (RA: Sigma R 2625) were added to the culture medium (2-/+ protocol). RA was reconstituted with 100% ethanol to prepare a stock solution. It should be noted that the effective RA concentrations at which ES cells grow into EBs may be considerably higher than those indicated in the text, because FBS contains significant levels of RA. Furthermore, cells within EBs may produce endogenous RA, possibly as a secondary effect of the initially added RA. However, we used conditions in which FBS did not contain exogenous RA as a negative control (stated control in the figures), and evaluated the results in terms of relative concentrations of RA. Recombinant mouse Sonic Hedgehog (Shh) protein (amino-terminal peptide) (Shh-N; R&D Systems Inc., 461-SH) and cyclopamine (0.1 µM, 1 µM, Toronto Research Chemicals Inc., C988400) were also added on day 2 of the experiment. For Noggin treatment, 10% (v/v) culture supernatant of Cos7

cells transfected with *Xenopus* Noggin/MC BOS (a gift of Y. Takahashi) (Kohyama et al., 2001; Tonegawa and Takahashi, 1998) (xNoggin conditioned medium) was added.

EBs were collected at day 6 of culture and allowed to settle to the bottom of the tube for a few minutes. The cells were then washed once with PBS and incubated with 0.25% trypsin–EDTA for 5 min at 37°C. The enzymatic reaction was quenched by addition of an equal volume of EB medium, and the cells were dissociated with a transfer pipette by triturating 30 times. The cells were then washed twice with serum-free α MEM and resuspended in Media hormone mix (MHM) medium, which contains DMEM/F-12 (1:1) (Gibco 12100-046, 21700-075), glucose (0.6%), glutamine (2 mM), sodium bicarbonate (3 mM), HEPES (5 mM), insulin (25 μ g/ml), transferrin (100 μ g/ml), progesterone (20 nM), sodium selenate (30 ng), and putrescine (60 nM) (all from Sigma except for DMEM/F-12) as described previously (Shimazaki et al., 2001). The dissociated EBs were plated on poly-L-ornithine/fibronectin-coated 10-mm cover glasses (Matsunami) at a cell density of 1.6×10^5 cells/0.75 cm² on a 48-well culture plate (Coaster) and allowed to differentiate for 24 h.

To clarify the effects of RA added at different points in time or of exposure for different periods of culture, ES cells were differentiated into EBs based on 2–/2+/2–, 2–/2+/2+ and 4–/4+ protocols (Suppl. Fig. 1). In the 2–/2+/2– and 2–/2+/2+ protocol, various concentrations of RA were added on day 2, and on day 4 the culture medium was replaced with freshly prepared medium containing the same concentrations of RA (2–/2+/2+ protocol) or no RA (2–/2+/2– protocol). In the 4–/4+ protocol, various concentrations of RA were added to the culture medium on day 4. Total RNA was isolated at day 0, 2, 4, 6, and 8 and processed for RT-PCR analysis.

Immunocytochemistry

Dissociated EBs were cultured for 24 h and fixed with 4% paraformaldehyde for 20 min at room temperature. The cells were rinsed with PBS twice and pretreated with PBS containing 0.3% Triton X-100 for 5 min at room temperature. After blocking in TNB buffer (Provided by NEN™ Life Science Products, Inc.) for 1 h at room temperature, the cells were incubated at 4°C overnight with the following antibodies: anti-Nestin (Rat-401, mouse IgG, 1:200), anti-Islet-1/2 (40.2D6, mouse IgG, 1:500), anti-Lim3 (67.4E12, mouse IgG, 1:1000), anti-HB9 (81.5C10, mouse IgG, 1:100), anti-Otx1 (Otx-5F5, mouse IgG, 1:500000), anti-Nkx2.2 (74.5A5, mouse IgG, 1:5000), anti-Pax7 (mouse IgG, 1:5000) (Developmental Studies of Hybridoma Bank: DSHB), anti- β III-tubulin (mouse IgG, 1:1000, Sigma T8660), anti-Olig2 (rabbit IgG, 1:30000) (Mizuguchi et al., 2001; Takebayashi et al., 2000), anti-Phox2b (rabbit IgG, 1:25000) (Pattyn et al., 1997), anti-Nkx6.1 (Ab174.3, rabbit IgG, 1:200000) (Jensen et al.,

1996), anti-Group B1 Sox [Sox1/(2)/3] (rabbit IgG, 1:10000) (Tanaka et al., unpublished). Anti-Group B1 Sox [Sox1/(2)/3] antibody is weakly reactive with Sox2, which is expressed not only by the neural primordium but by undifferentiated ES cells, and with Sox1 and Sox3 (with preference for Sox1 and Sox3 over Sox2). However, as all Group B1 Sox genes are expressed in neural primordium (Wood and Episkopou, 1999), we used this antibody to detect neural progenitors, by determining the immunostaining conditions under which undifferentiated ES cells, which were used as a negative control, did not stain (data not shown). Antigen retrieval was accomplished by incubating the samples in the boiled PBS for 10 min for anti-Islet-1/2 and anti-Lim3, in boiled Target Retrieval Solution (DAKO) for 10 min for anti-Nkx2.2, or in 1 N HCl at 30°C for 15 min for anti-Pax7. After washing with PBS three times, the cells were incubated for 1 h at room temperature with secondary antibodies conjugated with Alexa 488 or Alexa 568 (Molecular Probes). For anti-Islet1/2, anti-Lim3, anti-HB9, anti-Olig2, anti-Phox2b, anti-Otx1, anti-Nkx2.2, anti-Pax7, and anti-Nkx6.1 staining, we used biotinylated secondary antibodies (Jackson Immunoresearch Laboratory, Inc.) after exposure to 1% H₂O₂ for 15 min at room temperature to inactivate endogenous peroxidase. The signals were then enhanced with streptavidin-HRP (SA-HRP), followed by TSA™ Fluorescein System (NEN™ Life Science Products, Inc.). After washing with PBS, the samples were mounted on slides and examined with a universal fluorescence microscope (Axioptot 2, Carl Zeiss) and a confocal laser scanning microscope (LSM510, Carl Zeiss). The nuclei of all samples were stained with hoechst33342 (1 μ g/ml, Sigma B2261). For statistical analysis, at least 200 cells per cover glass were examined, and the numbers of cells that had immunoreacted with each antibody were counted and expressed as a percentage of the total number of cells whose nuclei stained with hoechst33342. The *P* values for statistical significance (*t* test) are stated in the figure legends.

Western blot analysis

Western blot analysis was performed by the previously established method. A 20 μ g protein sample of a total cell extract was run on 7.5–15% SDS-PAGE, transferred to nitrocellulose, and probed with each antibody. The blot was probed with the following antibodies: anti-Nestin (Rat-401, mouse IgG, Developmental Studies of Hybridoma Bank: DSHB), anti- β III-tubulin (mouse IgG, Sigma T8660), anti-Glial Fibrillary Acidic Protein (GFAP) (rabbit IgG, DAKO Z0334), anti-CNPase (mouse IgG, Sigma C5922), and anti-Shh N-terminal fragment (goat IgG, Santa Cruz sc-1194). Signals were detected with HRP-conjugated secondary antibodies (Jackson Immunoresearch Laboratory, Inc.) by using an ECL kit (Amersham Biosciences). Quantitative analysis was performed with Scion Image (Scion Corpo-

ration). The amounts of proteins loaded in each slot were normalized to those of α -tubulin.

RNA isolation and RT-PCR

RT-PCR analysis of at least two independent cultures was performed in most of the experiments, and were similar results obtained. Total RNA was isolated with Trizol reagent (Invitrogen™ 15596-018) and DNase I treatment, or by the RNeasy Mini Kit (Qiagen). Total RNA (1–3 μ g) was used to synthesize cDNA with 500 ng oligo-d(T)_{12–18} primers. The cDNA synthesis was performed at 42°C for 50 min in a final volume of 20 μ l according to the manufacturer's instructions for Superscript II RNase H⁻ reverse transcriptase (Invitrogen™). To analyze relative expression of different mRNAs, the amount of cDNA was normalized based on the signals from ubiquitously expressed β -actin mRNA. The PCR was carried out by using a KOD Plus kit (Toyobo) according to the manufacturer's standard protocol in a final volume of 25 μ l. Primer sequences and PCR cycling conditions will be provided upon request. To provide negative controls and exclude contamination by genomic DNA, the reverse transcriptase was omitted in the cDNA synthesis step, and the samples were subjected to the PCR reaction in the same manner with primer sets for β -actin, and are indicated at the bottom of each figure as RT(-). PCR products were electrophoresed in agarose gel, and bands were visualized with ethidium bromide under UV light. The identity of the PCR products was confirmed by sequencing.

Results

Differentiation potential of mouse ES cells regulated by RA

RA has been shown to be one of the most important extrinsic morphogens and precisely modulates the differentiation properties of ES cells into various cell types, including neural cells, skeletal muscle cells, adipocytes, cardiomyocytes, and vascular smooth muscle cells, in an incubation-time- and concentration-dependent manner (Rohwedel et al., 1999). To examine the concentration-dependent effects of RA on the differentiation of ES cells, we first differentiated ES cells by inducing the formation of EBs in the presence of various concentrations of RA. We also used Noggin, a secreted protein that plays a role in neural induction by inhibiting BMP-signaling (Finley et al., 1999; Gratsch and O'Shea, 2002; Kawasaki et al., 2000; Smith and Harland, 1992; Tropepe et al., 2001; Zimmerman et al., 1996), to investigate RA-independent neural differentiation. ES cells were plated onto bacteriological dishes and had been cultured for 6 days in medium containing various concentrations of RA (added on day 2) or xNoggin conditioned medium (Fig. 1), and they were analyzed by RT-PCR for markers of the three primary germ layers




Fig. 1. Experimental protocol for differentiation of ES cells with retinoic acid (RA) or xNoggin conditioned medium. ES cells were cultured in the bacteriological dish for 6 days and formed embryoid bodies (EBs). Various concentrations of RA were added on day 2 of EB formation. Then, EBs were dissociated and differentiated on poly-L-ornithine/fibronectin-coated cover glasses.

(Fig. 2). On day 2, *oct3/4*, which is a marker for undifferentiated ES cells, was expressed by both control and Noggin-treated EBs. From day 4 of EB formation onward, *oct3/4* expression was gradually down-regulated by RA in a concentration-dependent manner, and in a culture period-dependent manner, and it became undetectable on day 6 under all conditions, indicating that most of the ES cells had differentiated by 6 days of EB formation. On day 6, expression of *ck-17* (*cytokeratin 17*), a marker of epidermis (McGowan and Coulombe, 1998), and expression of *ngn2*, which is expressed in neuronal progenitors (Mizuguchi et al., 2001; Novitch et al., 2001; Ross et al., 2003), were enhanced by high-concentration RA treatment ($>10^{-7}$ M; high-RA), and thus ectodermal differentiation was promoted by exposure to high-RA. Expression of *ck-17* mRNA in undifferentiated ES cells, which also expressed *oct3/4* (Fig. 2), was also demonstrated in a previous study (Tropepe et al., 2001). In the control, Noggin, and low-RA-treated EBs, its expression coincided with expression of *oct3/4* at day 4, and was then down-regulated by day 6 along with extinction of *oct3/4*. In the high-RA-treated EBs, on the other hand, expression of *ck-17* mRNA was detected at day 4 and day 6, without expression of *oct3/4*. The expression of *ck-17* in the absence of expression of *oct3/4* can be understood as indicating promotion of epidermal differentiation in EBs treated with high-RA. Mesodermal differentiation, represented by expression of *brachyury*, which is essential for the formation and organization of mesoderm (Herrmann et al., 1990; Wilkinson et al., 1990), and expression of homeobox gene *nkx2.5*, the earliest known marker of cardiac development (Komuro and Izumo, 1993; Lints et al., 1993), were facilitated by low-concentration RA treatment (10^{-9} – 10^{-8} M; low-RA). Endodermal markers, including *gata4*, expressed in primitive endoderm (Arceci et al., 1993), and *pdx1*, expressed in developing pancreas (Jonsson et al., 1994; Offield et al., 1996), were




Fig. 2. Expression of markers of the three primary germ layers in EBs exposed to various concentrations of RA. RNA was isolated from ES cells (day 0) and EBs (days 2, 4, 6) and analyzed by RT-PCR for expression of markers of undifferentiated ES cells (*oct3/4*), endoderm differentiation (*pdx1* and *gata4*), mesoderm differentiation (*brachyury* and *nkx2.5*), epidermis differentiation (*ck-17*), and neural differentiation (*sox1* and *ngn2*). To normalize their expression to the amount of cDNA present in the sample, the cDNA for endogenous β -actin was amplified.

expressed unstably at low levels, and their levels correlated poorly with the concentrations of RA.

Neural induction of mouse ES cells by RA

It has been shown that neural differentiation of ES cells can be promoted by RA, especially by early exposure of EBs to relatively high RA concentrations (Bain et al., 1995, 1996; Fraichard et al., 1995; Gajovic et al., 1997; Renoncourt et al., 1998; Rohwedel et al., 1999; Strubing et al., 1995; Wichterle et al., 2002). However, as the effect of different RA concentrations had never been precisely described, we next investigated how RA promotes neural differentiation. EBs that had been cultured for 6 days were analyzed for differentiation markers of neural cells (progenitors, neurons, and glia) by Western blotting (Figs. 3A, B). Nestin, which is expressed in undifferentiated neural progenitors, was more strongly expressed in EBs treated with low-RA. Expression of β III-tubulin and GFAP, which are markers of differentiated neurons and astrocytes, respectively, increased in a concentration-dependent manner in EBs exposed to RA (Figs. 3A, B). By contrast, RT-PCR analysis on day 6 showed that expression of *sox1* (a marker of undifferentiated neural cells; Pevny et al., 1998; Wood and Episkopou, 1999) mRNA was higher in EBs treated with low-RA on day 6 (Fig. 2). Expression of CNPase, a marker of oligodendrocytes, was detected only slightly under all of the differentiating conditions, and its expression was not very strongly affected by the concentration of RA (Figs. 3A,B). To better understand the effects of RA on neural differentiation of EBs, we performed immunocytochemistry of markers of various neural lineages (Figs. 3C–E and 5A,B). EBs that had been cultured for 6 days were dissociated and differentiated on poly-L-ornithine/fibronectin-coated cover glasses for 24 h and then processed for immunocytochemistry of markers

of undifferentiated neural cells (Nestin, Group B1 Sox, Olig2) and postmitotic neurons (β III-tubulin). Olig2 is a basic-helix-loop-helix (bHLH) transcription factor that is expressed in most of the ventral neural progenitor cells around the period of neural tube closure (Takebayashi et al., 2000). Treatment of EBs with low-RA (10^{-8} M) induced a 1.6-, 3.0-, and 9.1-fold increase in Nestin-, Group B1 Sox, and Olig2-positive undifferentiated neural progenitors, respectively, over those treated with high-RA (2×10^{-6} M) (Figs. 3C–E). Treatment of EBs with high-RA (2×10^{-6} M) induced very few Nestin-, Group B1 Sox-, and Olig2-positive progenitor cells, and instead induced many β III-tubulin-positive postmitotic neurons [3.0-fold more than by treatment with low-RA (10^{-8} M)] (Figs. 3C–E and 5A). RT-PCR analysis showed that *olig2* was expressed in EBs treated with high-RA at day 4 and down-regulated by day 6, whereas it was expressed highly on day 6 in EBs treated with low-RA (Fig. 6A). These results indicate that higher concentrations of RA facilitate differentiation of neural progenitors into postmitotic neurons and glia, in contrast to lower concentrations of RA, which preferentially induce undifferentiated neural progenitor cells from ES cells; that is, that RA strongly promotes terminal differentiation of ES-cell-derived neural progenitors in a concentration- and culture-period-dependent manner in addition to its action that promotes neural induction of ES cells.

ES-cell-derived neural cells acquire positional identity through EB formation

To investigate how RA regulates the specification of rostral-caudal and dorso-ventral positional identity during EB formation, RT-PCR analysis of regionally specific markers was performed (Carpenter, 2002; Caspary and Anderson, 2003; Helms and Johnson, 2003; Hitoshi et al., 2002; Jessell, 2000; Marquardt and Pfaff, 2001;




Fig. 3. RA promotes neural differentiation in a concentration-dependent manner and regulates the differentiation of ES-cell-derived neural progenitors. (A) Western blot analysis of markers for neural differentiation in EBs cultured for 6 days. (B) Quantitative analysis was performed with Scion Image. The amounts of proteins were normalized to those of α -tubulin ($n = 3$, mean \pm SEM, *, $P < 0.05$ vs. control. †, $P < 0.05$ vs. RA 2×10^{-6} M). (C) Immunocytochemistry of dissociated EBs for Olig2 and Nestin. Nuclear localization of Olig2 in Nestin immunoreactive cells was confirmed by three-dimensional reconstruction of confocal microscopic images (right end of lower panels). (D, E) The proportions of cells positive for Nestin, Group B1 Sox, Olig2, and β III-tubulin among the total number of cells in dissociated EBs were determined by immunocytochemically. Immunoreactive cells as a percentage of the total number of cells counted on the basis of nuclear staining with hoechst33342 are shown ($n = 3$, mean \pm SEM, *, $P < 0.05$ vs. control. †, $P < 0.05$ vs. RA 2×10^{-6} M). The percentages of cells expressing Olig2, Group B1 Sox, and Nestin were higher in dissociates of EBs treated with low-RA ($< 10^{-8}$ M) than in EBs treated with high-RA ($> 10^{-7}$ M). Scale bar: 50 μ m.







Fig. 4. Concentration-dependent effects of RA on the specification of rostral-caudal positional identity of ES-cell-derived neural progenitors. (A) Effect of RA on rostral-caudal axis formations was analyzed by RT-PCR on days 0, 2, 4, and 6 of differentiation. The expression patterns are summarized in (B). RA caudalized ES-cell-derived neural cells in a concentration-dependent manner. Control and Noggin-treated-EBs expressed forebrain-type markers, whereas EBs treated with low-RA and high-RA expressed midbrain–hindbrain-type markers and spinal-cord-type markers, respectively.

Fig. 5. RA caudalizes EB-derived neurons in a concentration-dependent manner. (A) Immunocytochemical analysis of neural progenitors and neurons differentiated from dissociated EBs with Otx1, which is expressed in developing forebrain and midbrain, and Phox2B, Lim3, HB9, and Isl-1/2, which are expressed in developing motor neurons and their progenitors. Immunoreactive cells as a percentage of the total number of cells counted on the basis of the nuclear staining with hoechst33342 are shown in B ($n = 3$, mean \pm SEM, *, $P < 0.05$ vs. control. †, $P < 0.05$ vs. RA 2×10^{-6} M). (C) RT-PCR analysis of *phox2b* and *hb9*. Control and Noggin-treated EBs generated significant numbers of Otx1- and Group B1 Sox-positive anterior neural progenitors. Low-RA (10^{-9} – 10^{-8} M) induced many Phox2b-positive hindbrain brachial and visceral motor neurons and fewer Otx1/Group B1 Sox-positive anterior neural progenitors, whereas high-RA ($>10^{-7}$ M) induced more HB9-positive hindbrain and spinal cord somatic motor neurons without any Otx1-positive cells. Scale bar: 50 μ m.



Niederreither et al., 2000; Schuurmans and Guillemot, 2002; Wurst and Bally-Cuif, 2001). As shown in Fig. 4, EBs were caudalized in a concentration-dependent manner during the first 2 days of RA exposure (days 2–4). After day 4, control and Noggin-exposed EBs expressed genes specific to forebrain (*emx1*, *emx2*, *nkx2.1*, *otx1*, *otx2*) and midbrain–hindbrain (*otx1*, *otx2*, *en1*), but no hindbrain or spinal cord markers. EBs treated with low-RA mainly expressed midbrain–hindbrain markers (*otx1*, *otx2*, *en1*, *gbx2*, *hoxb1*, *hoxa2*, *hoxa3*), and did not express spinal cord markers (*hoxc4*, *hoxc5*, *hoxc6*, *hoxc8*, *hoxc10*). Expression of telencephalic markers (*emx1*, *emx2*, *dlx2*) in EBs treated with low-RA was lower than in control and Noggin-exposed EBs. However, at day 4, expression of one of the telencephalic markers, *foxg1*, was somehow highest in the EBs exposed to low-RA. On the other hand, high-RA induced expression of hindbrain and rostral spinal cord markers (*hoxc4*, *hoxc5*, *hoxc6*) and reduced expression of forebrain and midbrain markers. These patterns of gene expression were detected at day 4 and were maintained thereafter. The expression levels of enzymes involved in RA metabolism, *raldh2* and *cyp26a1* (Fig. 4A), were higher in EBs treated with high-RA, a finding that was consistent with the EBs exposed to high-RA acquiring the identity of rostral spinal cord, where the concentration of RA and the expression level of its synthesizing enzyme *Raldh2* are the highest in the developing CNS (Swindell et al., 1999). The RA catabolizing enzyme *Cyp26a1* may have been induced by high-RA as part of a negative feedback mechanism. The total gene expression patterns indicating rostro-caudal specification in EBs differentiated under different conditions are summarized in Fig. 4B. The concentration-dependent caudalization of EBs by RA treatment shown by the result of the RT-PCR analysis was confirmed by immunocytochemistry of dissociated EBs with antibodies for markers expressed in developing forebrain and midbrain (*Otx1*) (Acampora et al., 1998), visceral or brachial motor neurons in the hindbrain (*Phox2b*) (Pattyn et al., 2000), and somatic spinal motor neurons (*HB9*, *Lim3*) (Arber et al., 1999) (Figs. 5A,B). Virtually all of the marker-positive cells were also positive for either a neural progenitor marker Group B1 Sox, or pan-neuronal marker β III-tubulin. A significant number of cells derived from EBs and grown under all conditions expressed *Isl-1/2*, a marker of postmitotic cholinergic neurons, including not only spinal motor neurons but those in ventral forebrain (Kohtz et al., 2001; Wang and Liu, 2001). Somatic motor neurons of the hindbrain and spinal cord expressing *Lim3* and *HB9* were found more frequently when treated with high-RA, whereas hindbrain visceral or brachial motor neurons expressing *Phox2b* were found more frequently when treated with low-RA. By contrast, an enormous number of neural progenitors that were positive for both *Otx1* and Group B1 Sox and acquired anterior positional

identity were induced from control and Noggin-treated EBs, and less frequently from low-RA treated EBs, whereas no such cells were induced from high-RA-treated EBs. Taken together, these findings indicate that RA induced both caudalization of EBs based on the expression patterns of regionally specific genes during neural induction and neuronal differentiation in a concentration-dependent manner, resulting in significant generation of forebrain and midbrain (control and Noggin), hindbrain (low-RA), and spinal cord (high-RA) types of neural progenitors or neurons, respectively.

RA controls dorso-ventral axis formation

To determine the effect of RA on dorso-ventral axis specification of EB-derived cells, we investigated the expression of class I genes (*pax7*, *dbx1*, *dbx2*, *irx3*, *pax6*, whose expression is repressed by Shh in early CNS development) and class II genes (*nkx6.2*, *nkx6.1*, *olig2*, *nkx2.2*, whose expression is activated by Shh). These genes are differentially expressed along the dorso-ventral axis in the progenitor domains of developing hindbrain and spinal cord (Jessell, 2000). As shown in Fig. 6, EBs treated with low-RA expressed both class I and class II genes, indicating that they were composed of various populations that had acquired their identities throughout the dorsal to ventral neural tube. Interestingly, on the other hand, treatment with high-RA raised the expression levels of class I genes and significantly reduced those of class II genes except *olig2* at day 4, in comparison to treatment with low-RA. Thus, high-RA caused dorsalization of neural progenitor cells in EBs. To investigate the mechanism underlying the action of RA in specifying dorso-ventral identity, we investigated its effects on expression of the N-terminus of Shh protein (Shh-N) and *sonic hedgehog* (*shh*) mRNA. Mouse Shh is produced as a 49-kDa secreted protein that post-translationally cleaves to yield two mature proteins: an approximately 19-kDa N-terminal fragment that contains the signaling portion of the molecule and an approximately 27-kDa C-terminal fragment, which has auto-processing activity (Marti et al., 1995; Porter et al., 1995, 1996; Roelink et al., 1995). We found that expression of both the Shh-N protein and *shh* mRNA was significantly up-regulated by exposure to low-RA in day 4–6 EBs (Figs. 7A–C), but that further increasing the RA concentration ($>10^{-7}$ M) induced their down-regulation instead. More specifically, the RA-responsive increase in Shh-N expression appeared to be concentration-dependent up to 10^{-8} M, but was completely abrogated at 10^{-7} M and higher concentrations. On the other hand, the peak level of full-length Shh protein expressed in response to exposure to 10^{-8} M of RA was maintained even in EBs exposed to higher concentrations of RA. These results suggested that the ventralization of neural progenitors in EBs exposed to low-RA might be caused by an enhanced expression of Shh-N. However, we




Fig. 6. Specification of the dorso-ventral identity of ES-cell-derived neural progenitors is regulated by RA. (A) RT-PCR analysis of class I and class II genes, which define dorso-ventral positional identity. The expression patterns are summarized in (B). EBs treated with low-RA (10⁻⁹–10⁻⁸ M) expressed both class I and II genes (class II > class I), which indicated that both ventral and dorsal neural progenitors had been induced, whereas EBs treated with high-RA (>10⁻⁶ M) expressed only class I gene, indicating dorsal neural progenitors had been induced.

could not rule out the possibility of the opposite causal relationship; that is, that low-RA induced enhanced expression of Shh-N protein and the expression of *shh* mRNA resulted from the ventralization of EB-derived cells that had been induced by low-RA treatment through an unknown mechanism. To address this issue, we treated EBs exposed to RA with recombinant Shh-N protein and cyclopamine, an inhibitor of Shh signaling (Chen et al., 2002a,b; Incardona et al., 1998). In the absence of cyclopamine treatment, EBs exposed to low-RA expressed both class I (*pax7*, *dbx1*, *dbx2*, *irx3*, and *pax6*) and class II genes (*nkx6.2*, *nkx6.1*, *olig2*, and *nkx2.2*), thereby indicating both dorsal and ventral phenotype. Treatment with 1 μM cyclopamine strongly down-regulated the ventral class II genes (*nkx6.2*, *nkx6.1*, *olig2*, and *nkx2.2*) and some of the class I genes (*dbx1* and *dbx2*), indicating a dorsalized phenotype (Figs. 7D,E). In addition, exposure to 50 nM of recombinant Shh-N protein enhanced expression of class II genes (*nkx6.2*, *nkx6.1*, *olig2*, and *nkx2.2*) but reduced *pax7* expression. These effects were abrogated by treatment with 1 μM cyclopamine (Figs.

7D,E). EBs treated with high-RA expressed higher levels of class I genes (*pax7*, *dbx1*, and *dbx2*, *irx3*, *pax6*), but lower levels of class II genes (*nkx6.2*, *nkx6.1*, *olig2*, and *nkx2.2*), thereby indicating a more dorsal phenotype than after low-RA treatment. However, high-RA treated EBs were ventralized by treatment with exogenous Shh-N, as shown by the up-regulation of class II genes (*nkx6.2*, *nkx6.1*, *olig2*, and *nkx2.2*) and down-regulation of *pax7*, and these changes were also abrogated by 1 μM cyclopamine treatment (Figs. 7D,E).

This alteration of dorso-ventral identity by RA, Shh-N, and cyclopamine was confirmed by the immunostaining of dissociated EBs with antibodies against Pax7, Nkx6.1, and Nkx2.2 (Fig. 8). Virtually all the marker-positive cells also stained with the antibodies against Group B1 Sox or Nestin, indicating they are neural progenitor cells. It was noteworthy that Shh-N treatment could induce only Nkx6.1-positive but not Nkx2.2-positive neural progenitors in EBs treated with high-RA, indicating that the ventralmost neural progenitors could not be efficiently derived under such conditions, but that they were capable of increasing the